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Adipokines, factors produced by adipose tissue, may be proinflammatory (such as leptin and resistin) or anti-inflammatory (such
as adiponectin). Effects of these adipokines on the lungs have the potential to evoke or exacerbate asthma. This review summarizes
basic mechanistic data through population-based and clinical studies addressing the potential role of adipokines in asthma.
Augmenting circulating concentrations of adiponectin attenuates allergic airway inflammation and airway hyperresponsiveness
inmice.Murinedataissupportedbyhumandatathatsuggestthatlowserumadiponectinisassociatedwithgreaterriskforasthma
amongwomenandperipubertalgirls.Further,higherserumtotaladiponectinmaybeassociatedwithlowerclinicalasthmaseverity
among children and women with asthma. In contrast, exogenous administration of leptin results in augmented allergic airway
hyperresponsiveness in mice. Alveolar macrophages obtained from obese asthmatics are uniquely sensitive to leptin in terms of
their potential to augment inflammation. Consistent with this basic mechanistic data, epidemiologic studies demonstrate that
higherserumleptinisassociatedwithgreaterasthmaprevalenceand/orseverityandthattheseassociationsmaybestrongeramong
women, postpubertal girls, and prepubertal boys. The role of adipokines in asthma is still evolving, and it is not currently known
whether modulation of adipokines may be helpful in asthma prevention or treatment.
1. Introduction
Obesity is increasingly appreciated as a risk factor for asthma
a n dh a sb e e nt h es u b j e c to fm u l t i p l er e c e n tr e v i e w si nt h e
literature [1–3]. There is an immense interest in the potential
role of adipose tissue in the development or worsening of
asthma among obese individuals, particularly women. Adi-
posetissueisanactiveendocrineorgan,producingnumerous
energy regulating hormones including adiponectin, leptin,
and resistin. In obesity, serum concentrations of leptin
and resistin increase, while adiponectin decreases. The adi-
pose tissue of obese individuals is infiltrated with activated
macrophages. Current concepts suggest that, during devel-
opment of obesity, adipose tissue hypertrophy leads to local
tissue hypoxia, focal adipocyte necrosis, and consequent
recruitment of macrophages [4, 5]. Tissue hypoxia and
macrophageactivation,likelyconsequenttotoll-likereceptor
(TLR) signalling via fatty acids, then result in the genera-
tion and release of a variety of proinflammatory cytokines,
chemokines, acute phase proteins, and other moieties from
adipose tissue. Collectively with adipose tissue derived hor-
mones, these substances are referred to as adipokines. Serum
concentrations of many of these adipokines are not only
associated with body mass index (BMI) but are likely also
mechanistically related to many obesity dependent diseases
such as type II diabetes mellitus, steatohepatitis, atheroscle-
rotic cardiovascular disease, and hypertension. Here, we
consider the role of adipokines in obesity-related asthma.
In particular, this review summarizes basic mechanistic data
through population-based and clinical studies addressing
the hypothesis that adiponectin, leptin, and possibly resistin
may each have a role in asthma. The association between
obesity and asthma is complex and multifaceted and is likely2 Journal of Allergy
explained by many mechanisms, one of which involves these
adipokines.
2. Adiponectin
Adiponectin is an insulin sensitizing hormonethat also plays
a role in inflammation. Adiponectin inhibits effects of proin-
flammatory cytokines, such as tumor necrosis factor (TNF)-
𝗼 and interleukin-6 (IL-6), on endothelial and other cell
types[6–8]andalsoinducesexpressionofanti-inflammatory
cytokines (IL-10 and IL-1 receptor antagonist) [8–10]. How-
ever, adiponectin also has proinflammatory effects that
become manifest under selected conditions. For example,
adiponectin induces IL-6 and matrix metalloproteinase-1
secretion in the synovial tissue of patients with arthritis [11].
Adiponectin can also induce activation of the proinflamma-
tory transcription factor, nuclear factor (NF)-𝜅Bi nm o n o -
cytic cell lines [12], while inhibiting the same in endothelial
cells [13].
Curiously, even though visceral adipocytes are its most
important source [14], systemic adiponectin concentrations
are reduced in obesity [15]. Hyperinsulinemia, a common
consequence of obesity, as well as excess proinflammatory
cytokines (such as TNF-𝗼 and IL-6) that are produced in
obese adipose tissue, has been shown to inhibit adiponectin
mRNA expression in adipocytes and may contribute to
obesity-related reduction in systemic adiponectin concen-
trations [16–18]. Further, incomplete processing of mature
adiponectin protein, likely as a result of endoplasmic retic-
ulum stress, has been proposed to play a role in the decline in
serum adiponectin observed in obesity [19].
Adiponectin monomers have a globular head and a
collagen-like tail. However, adiponectin monomers do not
circulate. Instead, adiponectin multimerizes and circulates
in the blood as trimeric, hexameric, and higher order mul-
timeric forms that have low, medium, and high molecular
weights (LMW, MMW, and HMW), respectively, as shown in
Figure 1. A globular form can also be created at target organs
by proteolytic cleavage of the collagenous tail. Although this
isoform is biologically active, it is not clear that it exists
in the circulation. There are gender differences in both the
serumconcentrationandisoformdistributionofadiponectin
(Figure 1). Total serum adiponectin and particularly the
HMW isoform, is higher among women than men [20].
These differences develop during puberty and are the result
of inhibition of HMW adiponectin production by circulating
testosterone [21]. While the LMW and HMW isoforms of
adiponectin dominate in the serum of men and women,
respectively [22], the MMW isoform appears to dominate
in the sputum without any sex-related difference in concen-
trations [23]. MMW and HMW adiponectin isoforms also
dominate in the murine lung lining fluid [24]. Overall, there
is poor correlation between blood and airway concentrations
of total adiponectin or its isoform distribution [23, 25]l i k e l y
beca useinthea bsenceo finfla mma tio nadi po nectindoesno t
easilycrossthepulmonaryvasculaturetoaccessthelung(see
the following).
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Figure 1: Schematic representation of the sexual dimorphism of
the absolute concentrations of the circulating adiponectin isoforms.
Compared to men, women have higher absolute concentrations of
circulatingtotaladiponectin(meanvaluesof11.3versus23.5𝜇g/mL)
and all its isoforms [26]. When the isoforms are expressed as a
proportion of the total, women have higher proportions of high
(32% versus 26%) and medium molecular weight (39% versus 33%)
isoformsbutalowerproportionofthelowmolecularweightisoform
(28% versus 41%) than men [26]. The figure summarizes the data
published previously by Peake et al. [26] and has been reproduced
with permission from Curr Med Chem [27].
Adiponectin isoforms vary in efficacy. For example,
HMW adiponectin is the most biologically active isoform
with respect to insulin sensitivity [28, 29]. Similarly, HMW
adiponectin correlates inversely with cardiovascular risk fac-
tors (triglycerides, hypertension) and positively with cardio-
protective factors (high-density lipoprotein or HDL choles-
terol), even after controlling for BMI, whereas such corre-
lations are not observed for other isoforms of adiponectin
[30]. The activity of the various isoforms with respect to their
effects on the airway remains to be determined.
Several adiponectin binding proteins have been identi-
fied, including AdipoR1, AdipoR2, T-cadherin, and calreti-
culin. Adiponectin can also induce effects in a receptor-
independent fashion. Multiple cell types in the lung express
adiponectinbindingproteins,includingthebronchialepithe-
lium [31, 32], airway smooth muscle [33], and pulmonary
vasculature [34, 35]. Expression of AdipoR2 and T-cadherin
mRNA by bronchial epithelial cells is greater among obese
patients with asthma than obese controls [36]. Adiponectin
binding proteins differ in their affinity for the various
adiponectin isoforms. Globular adiponectin primarily binds
to AdipoR1, whereas full-length (multimeric) adiponectin
primarily binds to AdipoR2 [37]. AdipoR1 and AdipoR2
have been shown to result in peroxisome proliferator-
activated receptor (PPAR)-𝗼, adenosine monophosphate-
activatedproteinkinase(AMPK),andp38mitogen-activated
proteinkinase(MAPK)activation[37,38]. AdipoR1 and Adi-
poR2 exhibit ceramidase activity, and adiponectin augments
ceramide conversion to sphingosine-1-phosphate (S1P). In
fact,adiponectininducedAMPKactivationmaybemediated
through the actions of S1P. The ability of adiponectin to
inhibit apoptosis in cardiomyocytes and other cells mayJournal of Allergy 3
b et h er e s u l to ft h i sa b i l i t yt oc o n v e r tt h ep r o a p o p t o t i c
ceramide to the antiapoptotic S1P [39]. Because several S1P
receptors with diverse effects exist, it is conceivable that
the seemingly contradictory pro- and anti-inflammatory
effects of adiponectin result from stimulus and cell-type
specific differences in the expression of S1P receptors. It
has not been determined whether adiponectin couples to
ceramidaseactivityinthelungs,butadiponectindoesinhibit
apoptosis in bronchial epithelial cells [32], and loss of such
antiapoptotic effects may explain why adiponectin deficient
mice develop emphysema-like changes as they age [40].
Moreover, adiponectininduced effects in bronchialepithelial
cells include augmented wound healing and proliferation as
well as IL-8 release [31, 32]. The airways are therefore a likely
target of adiponectin.
T-cadherin appears to be important for adiponectin
transport into the lungs. The concentration of adiponectin
in murine bronchoalveolar lavage (BAL) fluid is relatively
high [31, 40]. Because adiponectin is not synthesized to any
physiologically meaningful extent in the murine lung [40],
i tm u s tb et a k e nu pi n t ot h el u n gf r o mt h eb l o o d .H o w e v e r ,
adiponectin does not enter the lung via simple diffusion
through gaps between endothelial cells. HMW adiponectin
dominates in BAL fluid in mice, with lesser amounts of
MMW adiponectin and very little LMW adiponectin [24,
34], a pattern opposite to that expected by diffusion. T-
cadherin is abundantly expressed on endothelial cells and
avidly binds HMW and MMW but not LMW adiponectin
[41, 42]. Furthermore, adiponectin is lower in BAL fluid
of otherwise na¨ ıve T-cadherin deficient versus wild-type
mice. These data are consistent with the hypothesis that
adiponectin binding to T-cadherin on pulmonary vascular
endothelialcellspermitsadiponectintransitacrossthesecells
by a vesicular transcytosis pathway in mice. Adiponectin
boundtoT -cadherinonendothelialcellsalsoappearstoserve
as a repository for adiponectin, since serum adiponectin
is markedly elevated in T-cadherin deficient versus wild-
type mice, and the marked adiponectin immunoreactivity
normally present on endothelial cells is absent in T-cadherin
deficientmice[24,34,41].Itisimportanttonotethatwhereas
T-cadherinappearstobeimportantfortransitofadiponectin
frombloodtolungsinna¨ ıve mice, this is not the case in mice
with pulmonary inflammation/injury sufficient to increase
alveolar capillary permeability. In both allergen exposed
a n do z o n ee x p o s e dm i c ew h i c hh a v em a r k e di n c r e a s e si n
BAL protein consistent with leak of serum proteins into
the alveolar spaces, there is also a marked increase in BAL
adiponectin [43, 44]. Moreover, under these circumstances,
T-cadherin deficiency no longer results in reductions in BAL
adiponectin, and BAL fluid becomes dominated by LMW
adiponectin [44], consistent with diffusion of adiponectin
through paracellular pathways between endothelial cells.
2.1. Adiponectin and Asthma. Given the presence of adi-
ponectin and its receptors in the lung and the declines in
adiponectin concentrations in obesity, it is conceivable that
the loss of the anti-inflammatory effects of adiponectin in
obesity contributes to asthma prevalence or severity. Below,
we discuss data exploring this hypothesis. We first discuss
studies performed in animals and then present data from
population-based and clinical studies in humans.
2.1.1. Animal Studies. In mice, obesity-related declines in
adiponectin appear to contribute to the development of type
2 diabetes mellitus and atherosclerosis. Exogenous adminis-
tration of adiponectin protects obese mice against these con-
ditions,whileadiponectinknockoutmicearesusceptible(see
[45]forreview).Shoreetal.[46]soughttodeterminewhether
the effects of adiponectin in the lung are consistent with a
possible role for this adipokine in asthma. To do so, they
administered exogenous adiponectin to lean allergen sensi-
tizedmiceduringacuteallergenchallenge.Mini-Alzetpumps
were used to allow for continuous infusion of adiponectin
t h r o u g h o u tt h ec h a l l e n g ep e r i o da n dr e s u l t e di na na p p r o x i -
mate 50% increase in serum adiponectin. Compared to vehi-
cle, adiponectin treatment resulted in a marked reduction
in allergen induced airway hyperresponsiveness (Figure 2).
Adiponectin treatment also caused an almost complete sup-
pression of eosinophil recruitment to the airways and of Th2
cytokineexpressioninthelungs.Ionescuetal.[47]obtaineda
similarresultinamurinemodelofchronicallergenchallenge.
They showed that intranasal administration of adiponectin
along with each allergen challenge resulted in a marked
suppression of allergen induced airway hyperresponsiveness
and airway inflammation, and also inhibited the increases
in airway smooth muscle thickness that are observed in
this model. Adiponectin also reduces the platelet-derived
growth factor (PDGF) or serotonin induced proliferation
of murine airway smooth muscle cells in culture (unpub-
lished observations), consistent with its inhibitory effects on
vascular smooth muscle proliferation [35]. Interestingly, in
rat vascular smooth muscle, the antiproliferative effects of
adiponectin are observed with the globular but not the full-
length isoforms, suggesting that proteolytic cleavage of this
adipokine is required for its biological effects on smooth
muscle [48].
Despite the marked reductions in allergic airways
responses observed with adiponectin treatment after acute
a l l e r g e nc h a l l e n g ei ns e n s i t i z e dm i c e[ 46], adiponectin defi-
ciency does not augment these responses in this model
[43, 50], although it does augment responses to chronic
allergen challenge [50]. It is conceivable that the differential
effects of adiponectin deficiency in acute versus chronic
allergenchallengemodelsr ela tetotheeffectsofthechallenge
on endogenous adiponectin. Shore et al. [46]r e p o r t e da
reduction in both serum adiponectin and in adipose tissue
adiponectin mRNA expression in mice after acute allergen
challenge,presumablyasaresultofspilloverofinflammatory
moieties from the airways to the blood. Such reductions
would limit differences between wild-type and adiponectin
deficient mice. In contrast, the chronic allergen challenge
model used [50] results in a much less intense inflam-
mation and presumably less extensive reduction in serum
adiponectin.
Studies addressing the nature of the receptors that con-
tribute to the protective effect of adiponectin for asthma on4 Journal of Allergy
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Figure 2: A schematic representation of the suggested role for
adiponectin in allergen induced asthma in mice, based upon the
work by Shore et al. [46]. This figure is as originally published
by Sood et al. [49].
the lung are more limited. Williams et al. observed a marked
reduction in allergen induced airway hyperresponsiveness,
eosinophil recruitment to the airways, Th2 cytokine expres-
sion, and mucous cell hyperplasia in mice deficient in T-
cadherin [43]. Importantly, these reduced responses to aller-
gen were not observed in mice that were bideficient in both
T-cadherin and adiponectin, indicating that adiponectin was
required for the effects of T-cadherin deficiency to be man-
ifest and therefore that the adiponectin binding properties
of T-cadherin were involved in the observed responses. The
data indicate that T-cadherin does not mediate the ability of
adiponectintoreduceallergicairwaysresponses.Instead,the
effects of T-cadherin deficiency were likely secondary to the
increased serum concentrations of adiponectin observed in
these mice.
Th ec e l lt y p et h a ti st h et a r g e to fe ff e c t so fa d i p o n e c t i n
that limit allergic airway responses has also not been
established. In addition to epithelial cells, endothelial cells,
and airway smooth muscle (see above), it is conceivable
that lung macrophages are involved. Eotaxin, an important
eosinophilchemotacticfactor,isreleasedfromculturedbone
marrow derived macrophages treated with IL-4 and TNF,
and adiponectin attenuates this release [50].Othershavealso
reported that adiponectin biases macrophages towards an
M2, less inflammatory phenotype [51], though there are also
reportsthatadiponectinincreasestheinflammatorypotential
of human macrophages [52]. Dendritic cells undergo func-
tional maturation in response to adiponectin [53],andTcells
do express adiponectin receptors [54], but adiponectin does
not affect T cell proliferation after allergen presentation by
dendritic cells [43, 52]. However, adiponectin does induce
increased IFN-𝗾 production by activated CD4+ T cells along
with increased expression of the transcription factor, T-bet,
indicatinggreaterTh1bias[52,53].SuchTh1biasingofCD4+
T cells might limit allergic airway responses that require Th2
cells.
I ti si n t e r e s t i n gt on o t et h a tc o m p a r e dt ow i l d - t y p e
mice,T-cadherindeficientmicewithhighserumadiponectin
also had reductions in BAL IL-17A expression after allergen
challenge [43]. Moreover, allergen induced increases in BAL
IL-17 were restored when the T-cadherin deficient mice were
also deficient in adiponectin [43]. The results indicate that
adiponectin may regulate IL-17A expression in the lungs.
Consistent with these observations, in mice challenged with
ozone (0.3ppm for 24–48), Kasahara et al. [44]o b s e r v e da
marked increase in IL-17A mRNA expression in adiponectin
deficient versus wild-type mice. Both pulmonary interstitial
macrophages and 𝗾𝗿 T cells produced IL-17A after ozone
exposure and may have been the targets of adiponectin.
Despite the largely anti-inflammatory effects of adi-
ponectin in the setting of allergic airways disease, adi-
ponectin also appears capable of causing proinflamma-
tory/proasthmatic effects in the lungs in response to other
stimuli.Followinghighdoseacuteozoneexposure(2ppmfor
3h), mice develop airway hyperreactivity and a neutrophilic
inflammation characterized by increases in acute phase
cytokinesandchemokines.Theseresponsesareattenuatedin
mice deficient in adiponectin [24]. Nevertheless, compared
to wild-type mice, responses to acute ozone exposure are
unaffected in transgenic mice that substantially overexpress
adiponectin [24]. These results suggest that normal endoge-
nous levels of adiponectin are sufficient to produce maximal
augmentation of proinflammatory effects of acute ozone
exposure. Under such circumstances, further increasing of
adiponectin by transgenic overexpression would not be
expected to have any additional effects, as observed.
2.1.2. Human Studies. There are also data from human sub-
jects suggesting a protective role for adiponectin in asthma.
It is important to note that reagents necessary to perform
mechanistic studies in humans are still lacking and awaiting
a better understanding of adiponectin signalling processes.
Hence,studiesinhumansubjectshavebeenmostlylimitedto
associationsbetweencirculatingorlunglevelsofadiponectin
and clinical disease outcomes with limited data on inflam-
matory outcomes (Table 1). The assumption underlying such
studies is that if adiponectin is mechanistically related to
asthma, then there ought to be associations between disease
prevalence or severity and adiponectin concentrations. In
evaluating these studies, one must bear in mind that even
in animal studies the target cell mediating the apparent
beneficial effects of adiponectin has not been established.
Therefore, it is not clear whether blood adiponectin, lung
adiponectin, or the adiponectin concentration in some other
target tissue, for example, the lymph nodes or perilymphatic
fat tissue, is appropriate to examine. This is a particularly
difficultissuegiventhelackofcorrelationbetweenbloodand
lung adiponectin (see above).
(i) Asthma Prevalence. Some but not all studies demonstrate
that low serum total adiponectin concentrations are asso-
ciated with a greater risk for asthma among women and
peripubertal girls (see Table 1).
Thestrongestevidencesupportingarelationshipbetween
adiponectin and asthma comes from a US-based longitu-
dinal cohort that showed that low serum total adiponectinJournal of Allergy 5
Table 1: A tabular summary of the current evidence supporting the roles for systemic adiponectin or leptin with respect to asthma in human
subpopulations.
Adiponectin-asthma association Leptin-asthma association
Asthma prevalence Asthma severity Asthma prevalence Asthma severity
Males
Prepubertal boys Inadequately studied (#)
Beneficial effect on exercise
induced bronchoconstriction
and FEF25–75% [55, 56]( ∗)
Harmful effect [57–59]
(†)
Harmful effect on clinical
o u t c o m e s ;p e a ke x p i r a t o ry
fl o wr a t e s ;e x e r c i s ei n d u c e d
bronchoconstriction
[56, 60, 61]( †)
Peri/postpubertal
boys No effect [55]( ‡)
Beneficial effect on clinical
outcomes and FEV1/FVC ratio
[62]( ∗)
No effect [55]( ‡)N o e ff e c t [ 62]( ‡)
Men
Unclear effect—no effect on
clinical outcomes [63, 64];
harmful effect on prevalent
reversible airflow obstruction;
beneficial effect on exhaled
nitric oxide [63, 65]( ‡)
Harmful effect on clinical
outcomes [49]( †) No effect [64–66]( ‡) Inadequately studied (#)
Females
Prepubertal girls Inadequately studied (#) Inadequately studied (#) Inadequately studied (#)
Harmful effect on clinical
outcomes [61]( †)
Peri/postpubertal
girls Beneficial effect [67]( ∗)
Possible beneficial effect on
clinical outcomes and
spirometry [68]( ∗)
Harmful effect [67]( †)
Harmful effect on clinical
outcomes [62]( †)
Premenopausal
women
Beneficial effect [36, 63, 69]
(∗)
Beneficial effect on clinical
outcomes [49]( ∗) Harmful effect [66]( †) Inadequately studied (#)
Postmenopausal
women Inadequately studied (#) Beneficial effect on clinical
outcomes [70]( ∗) Harmful effect [70]( †)
Harmful effect on clinical
outcomes and FEV1/FVC
ratio [70]( †)
Note1: Inadequately studied, beneficial; and harmful associations as well as no effects or unclear effects are depicted by different symbols (#, ∗, †,a n d‡).
concentrations (<7m g / L )a r ea s s o c i a t e dw i t hi n c r e a s e dr i s k
for incident asthma among women and that this association
was significantly stronger among current smokers versus not
currently smoking women [69]. Further, low serum total
adiponectin was a stronger predictor than BMI for incident
asthma among women [69]. Interestingly, the converse was
not true, that is, prevalent asthma did not predict low future
serum total adiponectin concentrations [69].
Unlike the above-mentioned longitudinal study [69],
five relatively large human studies cross-sectionally analyzed
the association between serum adiponectin and prevalent
asthma, independent of obesity [55, 63–65, 67]. While three
of these five studies showed no significant associations [55,
64, 65] ,t w oo t h e rs t u d i e ss h o w e dt h a tl o ws e r u mt o t a l
adiponectin was associated with greater odds for asthma
among premenopausal women and peripubertal girls [63,
67]. Although the birth cohort study in New Zealand
showed that serum total adiponectin concentrations were
not associated with prevalent asthma diagnosis overall, sex-
specific analyses showed that high serum total adiponectin
among men was associated with lower exhaled nitric oxide
levelsbutconfusinglygreateroddsforprevalentbronchodila-
tor responsiveness [65]. Thus, the spirometric data and
exhaled nitric oxide data show contradicting physiologic and
anti-inflammatory effects of adiponectin among men [65].
Generally speaking, many of the above-mentioned cross-
sectional analyses were limited by their smaller numbers of
girls/women, modest effect sizes, and lower prevalence of
asthma and obesity in populations outside the United States
[55, 64, 65]. Compared to the inconclusive adiponectin-
asthmastudies[55,64,65], the US-based longitudinal cohort
[69] possibly had a greater statistical power due to both a
planned selection of large numbers of African Americans
as well as a fortuitous selection of large numbers of obese
subjectsandsmokers—thesepopulationgroupsareknownto
be particularly associated with low serum total adiponectin
concentrations [14]. The longitudinal study further found a
nonlinear relationship between serum total adiponectin and
riskforincidentasthma(Figure 3)[69].Sincetherelationship
may show a threshold effect that is only seen with the lowest
tertileofserumadiponectinconcentration(at<7mg/Linthat
study),itisimportanttohaveadequatenumbersinthisgroup
for any study to demonstrate a significant effect on incident
asthma. This may explain the discrepant results from other
s t u d i e si nt h i sfi e l d[ 55, 64, 65, 69].
Another explanation for these apparent discrepancies is
that serum concentration of adiponectin may be a poor
s u r r o g a t ef o rt h ea d i p o n e c t i nt h a ta c t u a l l yi m p a c t sa s t h m a .6 Journal of Allergy
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Figure 3: Nonlinear relationship between serum adiponectin and
risk of incident asthma in a US-based longitudinal study [69].
The depicted relationship may show a threshold effect that is only
seen with the lowest tertile of serum adiponectin concentration.
The symbol
∗ represents a significant (𝑃 < 0.05)c o m p a r i -
s o nw i t hr e s p e c tt ot h eh i g ht e r t i l e .I na n o t h e rU S - b a s e dc r o s s -
sectional study, a similar threshold effect was seen between the
highestquartileofserumleptinconcentrationandprevalentasthma
in women [66]. Reproduced with permission of the American
Thoracic Society. Copyright © 2013 American Thoracic Society.
Official Journal of the American Thoracic Society [69].
I nap r e l i m i n a rys t u d yb ySoode tal .o nn o n s m o k e r s ,s p u t u m
totaladiponectinconcentrationswere lower amongasthmat-
ics than controls [23]. In fact, low sputum adiponectin pre-
dicted asthma status better than other measures of adiposity
including serum adiponectin, serum leptin, BMI, or DEXA
measures of fat and lean mass in that study [23]. On the
other hand, several other small case-control studies failed
to find any difference in BAL adiponectin concentrations
between asthmatics and controls, after matching or adjusting
for obesity [25, 70–72]. One explanation for the discrepant
findings between these studies is that sputum adiponectin
may be a relatively stronger measure than BAL adiponectin
for examining this association [23, 25, 70–72], since the
formerisapproximately40timesmoreconcentratedthanthe
latter.
Although it is certainly possible that adiponectin does
notmodifyasthmainhumans,anotherpotentialexplanation
for discrepant findings between studies lies in the possible
nonlinear effects of adiponectin that are missed by linear
statistical modelling. These effects may be threshold effects
(i.e., manifest only when a critical threshold in serum con-
c e n t r a t i o n si sr e a c h e d ,a ss u g g e s t e db ySo o de ta l .[ 69]) or U-
shapedeffects(withassociationsapparentatbothextremesof
serum concentrations).
(ii) Asthma Severity. Data here are limited, but higher serum
total adiponectin concentrations may be associated with
lower clinical asthma severity among children (particularly
boys) and women with asthma but interestingly greater
diseaseseverityamongmen(Table 1).Unlikeclinicalseverity
measures, adiponectin is not associated with inflammatory
asthma measures in a limited number of studies.
In a large community-based cross-sectional study of
subjectswithasthma,Soodetal.showedthathighserumtotal
adiponectinwasassociatedwithmorefrequentactivedisease
(including more frequent use of any asthma medication)
and greater number of respiratory symptoms and asthma
medications among men with asthma but beneficial effects
among women with asthma, with significant sex-specific
interactions [49]. These findings in women [49]w e r ec o n -
sistent with those of another small study of postmenopausal
women with asthma that showed that high serum total
adiponectin was associated with milder clinical severity of
disease (mean values 16.6ng/mL in mild to moderate asthma
versus 9.8ng/mL in severe asthma); men with asthma were
notincludedinthatstudy[70].Similarly,amongpostpubertal
obese girls who underwent weight loss, a modest increase
of 28% in baseline serum total adiponectin was associated
with an increase in spirometric parameters and reduction
in asthma severity in subjects with asthma—this analysis
was however limited by inadequate adjustment for the con-
founding effect of decrease in BMI [68]. Unlike clinical and
lung function measures, lung inflammatory biomarkers have
not been shown to be associated with adiponectin (in either
serum or bronchoalveolar lavage fluid) [25].
Pediatric studies, examining mostly prepubertal and
peripubertal asthmatic boys, show a consistent trend. High
serum total adiponectin concentrations were associated with
less severe exercise induced bronchoconstriction [56]a sw e l l
as fewer maximum asthma symptom days; fewer asthma
exacerbations; higher FEV1/FVC ratio [62], and higher
FEF25–75% values [55].
In a small study of obese women undergoing bariatric
surgery,adiponectinmRNAexpressioninvisceralabdominal
(omental) adipose tissue from asthmatics was lower than
that from controls, even after adjustment for BMI, and even
though no differences in serum adiponectin concentrations
were reported between the two groups [36]. Thus, it may
b et h a ta d i p o s et i s s u ea d i p o n e c t i nm R N Ae x p r e s s i o ni s
simply a marker for overall adipose tissue-dependent effects
that impact asthma, perhaps through other aspects of the
systemic inflammation of obesity. Such an explanation could
explain why anti-inflammatory effects of serum adiponectin
on asthma outcomes appear stronger in prepubertal boys
than men. In prepubertal boys, testosterone effects on
s e r u ma d i p o n e c t i na r en o ty e tf u l l ym a n i f e s t ,s os e r u m
adiponectin is more closely representative of other obesity-
r e l a t e de ff e c t si nt h ea d i p o s et i s s u e .T - c a dg e n o t y p ec o u l d
also impact the fidelity of serum adiponectin in reporting
adipose tissue dependent events. Reports from several large
genome wide association studies indicate that variation in
serum adiponectin concentrations among humans is in part
explained by single-nucleotide polymorphisms (SNP) in the
promoter of the T-cad gene [73, 74]. Given the marked
increase in serum adiponectin induced by T-cadherin defi-
ciency in mice [24, 43], along with observed reductions
in pulmonary T-cadherin expression induced by allergic
airways inflammation [43, 46], it is also possible that asthma
itselfinterfereswiththeabilityofserumadiponectintoreport
events occurring in adipose tissue.Journal of Allergy 7
Another explanation for the data from the morbidly
obese asthmatics undergoing bariatric surgery is that the
change in adiponectin expression was a consequence and
not a cause of asthmatic bronchoconstriction. Indeed, others
have shown that acute severe asthma exacerbations result
in a transient decrease in serum adiponectin concentrations
[70], similar to the reductions observed in mice challenged
with allergen [46], whereas bronchoprovocation from exper-
imentalinhalationalallergenchallengedoesnotacutelyaffect
serum adiponectin concentrations [75], perhaps because the
bronchoconstriction is so transient. Adipose tissue hypoxia
is thought to be central to obesity-related adipose tissue
inflammation [4], and it is likely that during severe asthma
exacerbations, ventilation perfusion mismatch, and conse-
quent hypoxemia would worsen this adipose tissue hypoxia
and thus decrease adiponectin expression. Alternatively, sys-
temic spillover of inflammatory moieties derived from the
lung could impact adipocyte gene expression, as discussed
above. While this spillover may not be significant in stable
asthma [69] or transient asthma exacerbation [75], it may
become manifest in either inadequately controlled asthma in
morbidly obese subjects [36] or during a severe acute asthma
exacerbation [70].
In summary, adiponectin is present in the lung, and
adiponectin receptors are expressed on key lung cells. There
are relatively strong data indicating that adiponectin limits
allergic airways responses in lean mice, though in models
of non allergic asthma, such as ozone exposure, adiponectin
paradoxically promotes rather than inhibits airway hyperre-
sponsiveness. Similarly, it is possible that proinflammatory
airway effects of adiponectin dominate under certain physio-
logic conditions in humans, while anti-inflammatory airway
effects dominate under others. For instance, in subjects
with chronic obstructive pulmonary disease (COPD), an
inflammatory obstructive airway disease related to asthma,
proinflammatory airway effects of adiponectin appear to
dominate [31, 76–79]. This may also be the case among men
with asthma [49]. On the other hand, anti-inflammatory
airway effects of adiponectin may dominate among women
a n dc h i l d r e n ,a l t h o u g ht h el i t e r a t u r ei sn o tc o n s i s t e n t .S o m e
of the lack of consistency of the human data may relate
to the inadequacy of serum total adiponectin as a marker
of the concentrations of relevant isoforms at target cells
within the lung. It also remains possible that the observed
associations are the result of the ability of serum adiponectin
toreportothereventsoccurringinadiposetissuethatimpact
asthma. Further understanding of the adiponectin target
cells and signalling pathways might help establish whether
a d i p o n e c t i nh a sac a u s a lr o l ei nh u m a na s t h m aa n df u r t h e r
allow for therapeutic strategies that harvest the beneficial
while limiting the deleterious effects of this adipokine.
3. Leptin
The hormone leptin, which derives its name from the Greek
wordleptos,meaningthin,isa16kDproteinderivedfromthe
obese(ob)geneandisexpressedpredominantlyinadipocytes
[80] .C o n s e q u e n t l y ,l e p t i ni sp r o d u c e di np r o p o r t i o nt o
a d i p o c y t em a s s ,a n dl e p t i nc o n c e n t r a t i o n sa r e4 – 6t i m e s
greater in severely obese compared to lean human subjects
[81]. Serum leptin concentrations increase with feeding and
in infectious and inflammatory states [82, 83]. Serum leptin
concentrations also display a circadian rhythm, with a nadir
around 8 in the morning[84]. Women and postpubertal girls
have 40–200% higher concentrations of circulating leptin
than their male counterparts, after adjustment for percent
body fat [85–88]. The rate of increase of circulating leptin
concentrations with BMI is about three-fold more rapid in
w o m e na si nm e n[ 89]. Although estrogen supplementation
increases and testosterone supplementation decreases leptin
concentrations [86, 90], sex differences in circulating leptin
are not entirely explained by either sex hormones or body fat
distribution [87]. Instead, these sex differences may involve
g r e a t e rl e p t i ng e n ee x p r e s s i o ni ns u b c u t a n e o u st h a nv i s c e r a l
adipose tissue [91] (subcutaneous adipose tissue is more
abundant in women) and/or greater release of leptin from
nonadipose sources [92]. Leptin can be expressed by various
cell types in the human lung, including bronchial epithelial
cells and alveolar type II pneumocytes and macrophages
[93, 94]. Whether these cells result in leptin production that
issignificantcomparedwiththatprovidedthroughtheblood
remains to be established. However, the observations that
airway leptin concentrations (measured in either sputum
or BAL fluid) are strongly correlated with serum leptin
concentrations (𝑟
2 of 0.61 and ≥0.55 for sputum and BAL
fluid, resp.) [23, 25] suggest that pulmonary sources may
be of limited physiological importance. Such correlations
also suggest that, in contrast to adiponectin, leptin is readily
transported from the blood to the lung.
Leptinmediatesitseffectbybindingtotheleptinreceptor
(OB-R), a single membrane spanning receptor of the class
I cytokine family with closest homology to gp130 of the IL-
6 family of cytokine receptors. Several OB-R variants are
generated by alternative splicing. The intracellular domain of
each of these, except OB-Re, which lacks the transmembrane
domain and is a soluble receptor, contains an interaction
motif for members of the janus kinase (JAK) family of
tyrosine kinases. However, only the long form, OB-Rb,
containsabindingmotifformembersofthesignaltransducer
and activator of transcription (STAT) family of transcription
factors[95].Followingleptinbinding,homo-oligomerization
of leptin receptors occurs. JAKs, which are constitutively
associated with the receptors, become phosphorylated, and
in turn tyrosine phosphorylates the receptor itself creating
dockingsitesforSH2domainsinSTATs.JAKsthenphospho-
rylate the STATs leading to their nuclear translocation and
to gene transcription. Receptor phosphorylation also leads
to recruitment of adaptor proteins that result in activation
of mitogen-activated protein kinase (MAPK), phosphatidyli-
nositol 3-kinase (PI3K), and mammalian target of rapamycin
(mTOR). AMPK is also activated by leptin [96]. Ob-Ra is
expressed in the lung, where it accounts for the majority
of Ob-R expression [97], although it is unclear whether the
receptor isoforms, which lack the STAT binding domain, are
capable of signalling in vivo [96]. The lung is also among the
peripheral tissues with the highest OB-Rb expression [97].8 Journal of Allergy
Pulmonaryandbronchialepithelialcellsexpressleptinrecep-
tors [94, 98], as do airway smooth muscle cells [99].
Leptin plays a key role in the regulation of appetite,
metabolism, and body weight, and both leptin deficient
and OB-Rb deficient mice are massively obese [100, 101].
Leptin also has profound effects on both innate and adaptive
immune system that may impact asthma. Leptin promotes
neutrophil chemotaxis and generation of reactive oxygen
species, induces activation of NK cells, and also promotes
macrophage activation, phagocytosis, and cytokine release
[102] .Th ea b i l i t yo fl e p t i nt ou p r e g u l a t el e u k o t r i e n eb i o s y n -
thesis in alveolar macrophages [103]m a yb ep a r t i c u l a r l y
relevanttoasthmagiventhepotencyofcysteinylleukotrienes
as bronchoconstrictors. The observation that leptin deficient
mice have thymic atrophy [104] emphasizes the role of leptin
in adaptive immunity. CD4+ T cells express OB-Rb, and
leptin induces proliferation of na¨ ıve but not memory T cells
[104]. Leptin also differentially affects cytokine production
i nTh 1a n dTh 2c e l l s ;l e p t i ni n c r e a s e sp r o d u c t i o no fTh 1
cytokines including interferon-𝗾 but suppresses production
of Th2 cytokines including IL-4 [104]. It is increasingly
appreciated that IL-17 may contribute to severe asthma. It is
interesting, in this context, that when purified na¨ ıve splenic
CD4+TcellsaregrownunderTh17biasingconditions,leptin
administration augments Th17 cell generation [105]. Leptin
also inhibits the function of regulatory T cells (Tregs) [106],
which would be expected to augment allergen induced T cell
activation.
Effects of leptin on lung cells might also impact asthma.
Bronchial epithelial cells are increasingly recognized as
contributing to asthmatic airway inflammation. Bronchial
epithelial cells express leptin receptors, and leptin causes
epithelial cell proliferation and mucin protein expression
[94, 98, 107]. Airway smooth muscle cells also express leptin
receptors capable of STAT-3 phosphorylation, and leptin
inhibits PDGF induced proliferation in these cells [99].
Leptin also promotes the ability of PDGF to induce VEGF
release from airway smooth muscle cells [33]a n dr e d u c e s
the ability of IL-13 stimulated airway smooth muscle cells
to produce eotaxin but has no effect on airway smooth
muscle cell contraction [99]. Leptin receptors are expressed
in mast cells both in the lungs and other tissues [108], but the
p r eciseeff ectso flep tino np ulmo na rymas tce llsr ema int obe
established.
3.1. Leptin and Asthma. Given the effects of leptin on the
immune system and the lung, it is conceivable that obesity-
related increases in leptin could initiate or worsen asthma.
Datafrombothanimalandhumanstudiesthathaveexplored
this hypothesis are discussed below.
3.1.1. Animal Studies. Shore et al. [109] examined allergen
sensitized and challenged mice in which leptin was experi-
mentally increased by continuousinfusion of leptin viamini-
Alzet pumps. Compared with saline, leptin had no effect on
airway responsiveness in unchallenged mice but increased
allergen induced airway hyperresponsiveness (Figure 4).
However, neither BAL eosinophils nor Th2 cytokines were
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Figure4:Aschematicrepresentationofthesuggestedroleforleptin
in allergen induced asthma in mice, based upon the work by Shore
et al. [109]. Reproduced with permission from Biochimie [112].
affectedbyleptintreatment,suggestingthatleptindependent
modifications in airway hyperresponsiveness were indepen-
dent of effects on T cells. Although it is conceivable that
leptineffectsonmastcellscouldhaveplayedarole,especially
sinceleptintreatmentdidresultinincreasedserumIgE[109],
the model used was not one that is mast cell dependent.
Instead, effects of leptin on the innate immune system
m i g h th a v el e dt ot h eo b s e r v e di n c r e a s ei na i r w a yh y p e r r e -
sponsiveness. In lean mice, leptin treatment that results in
serum leptin concentrations consistent with those observed
in obesity, increases inflammatory responses to acute ozone
exposure [100]. Such exposures result in TLR activation
[110]. However, fasting, which substantially reduces serum
leptin,hadnoeffectonozoneinducedinflammation,norwas
ozone induced inflammation affected in fasted mice when
serum leptin was returned to normal levels by exogenous
administration [111]. Taken together, the data indicate that
leptin induced augmentation of the inflammatory response
to ozone requires increases in serum leptin above those
normally observed in lean mice, that is, increases such as
t h o s eo b s e rv e di no b e s i t y .
Leptin deficient (ob/ob) and leptin receptor deficient
(db/db) mice each exhibit innate airway hyperreactivity [100,
101]. Arteaga-Solis et al. [113] recently reported that this air-
way hyperreactivity may be the result of loss of central effects
ofleptinthatinhibitparasympatheticdrivetoairwaysmooth
musclecells,sincethechangesinpulmonarymechanicswere
alleviatedinmicewithparasympatheticblockade.Shoreet al.
[109] did not observe this apparent bronchodilatory effect
afterexogenousadministrationofleptin;innonallergicmice,
airway responsiveness was similar in mice treated with saline
or leptin. However, it is conceivable that exogenous leptin
was unable to cross the blood brain barrier to any substantive
extent, limiting any central effects on parasympathetic drive.
N e v e r t h e l e s s ,i ti su n l i k e l yt h a tt h ei n n a t ea i r w a yh y p e r r e a c -
tivityobservedinob/ob and db/db mice[100,101]issolelythe
result of loss of bronchodilatory effects of leptin, since this
airwayhyperreactivityisalsoobservedinothertypesofobese
mice with elevated serum leptin [114, 115].Journal of Allergy 9
3.1.2. Human Studies. Studies in human subjects have been
mostly limited to associations between circulating or lung
levels of leptin and clinical disease outcomes such as asthma
prevalence or severity. Data on inflammatory outcomes is
very limited. Further, since there are no longitudinal or
interventional studies examining this association, the direc-
tion of causation for this association cannot be definitively
established. Our understanding of the effect of leptin on
asthma in humans, independent of the confounding effect of
BMI, is therefore still evolving (see Table 1).
(i) Asthma Prevalence.S o m eb u tn o ta l ls t u d i e si n d i c a t et h a t
high serum leptin concentrations are associated with greater
odds for asthma prevalence, particularly among prepuber-
tal boys, peripubertal and postpubertal girls, and women
(Table 1). The data suggest that this association may be more
consistent in children than in adults.
3.1.3. Population-Based Studies. A large cross-sectional ana-
lysis of participants of the US-based Third National Health
and Nutrition Examination Survey (NHANES III) showed
that women with high serum leptin concentrations (>21.9
ng/mL)hadgreateroddsforasthmathanthosewithlowcon-
centrations, independent of triceps skin fold thickness. This
association was stronger among premenopausalwomen than
postmenopausal women [66]. These findings were, however,
notconfirmedbySutherlandetal.inapopulation-basedbirth
cohort of approximately 1,000 young adult New Zealanders
[65]o rb yJ a rt tietal .[64]inalargesequentialcross-sectional
study set within an established Finnish cohort. There are
various reasons why the findings from the U.S-based cohort
were not reproduced in other cohorts. First, the prevalence
and severity of obesity in these cohorts were lower relative to
theUnitedStateswhichtruncatesthehighendoftherangeof
systemic leptin concentrations studied. This is an important
limitationofthesestudiessincetheUS-basedstudysuggestsa
nonlinearorthresholdeffectforthehighestquartileofserum
leptin concentrations on asthma risk [66]. Further, the New
Zealand cohort used nonfasting measures of serum leptin,
resultinginnondifferentialinformationbiasinwhichthebias
maycontributetowardsalackofassociationduetoincreased
variability[65].InsufficientpowerortypeIIerrorisapossible
explanation for the discrepant results as well. A sample size
of approximately 407 women in the New Zealand study [65]
and1,446youngwomenintheFinlandstudy[64]wassmaller
than that analyzed in the U.S.-based study [66].
3.1.4.Clinic-BasedStudies. Theassociationbetweensystemic
leptin and asthma prevalence is more consistent in clinic-
based studies of children than adults. In two case-control
studies of prepubertal children by Guler et al. and Gurkan
et al., serum leptin concentrations were higher in asthmatics
than controls, independent of BMI [57, 60]. Additionally,
Guler et al. found that this association was the strongest
a m o n ga t o p i cb o y s[ 57]. The study of Gurkan et al. also
included mostly boys [60]. Similarly, in another study of
peripubertal children, mostly boys, serum leptin concentra-
tions in overweight asthmatics were twice that of controls of
similar BMI (median values 30.8 versus 14.3ng/mL) [58].
Data in adults from clinic-based studies are less con-
vincing. Lessard et al. showed higher sputum leptin con-
centrations in adult asthmatics than controls, but these
findings may be confounded by the remarkably different
BMI levels between the groups [116]. While one small case-
control study showed greater serum leptin concentrations
among adults with asthma than controls (mean values 24.8
versus 13.7ng/mL) [70], others failed to show any difference
in serum or BAL leptin concentrations between the two
groups, after adjusting for obesity [25, 36, 71, 72, 116]. Of
note,theclinic-basedstudieshadsignificantlysmallersample
s i z e st h a nt h ep o p u l a t i o n - b a s e ds t u d i e sw h i c hm a yh a v e
contributed to discrepant findings due to inadequate power.
It is unclear why the leptin-asthma association is more
consistent among children than adults. A possible explana-
tion may be that asthma in children may be a more uniform
p h e n o t y p e ,w h e r e a si na d u l t si ti sah e t e r o g e n e o u sc o l l e c t i o n
ofphenotypesandthatleptinmaybedifferentiallyassociated
with one of the various asthma phenotypes. Indeed, the
as thmap heno typeinc hildr enismo r elik el yt obea t o p ictha n
that in adults. Atopic status may modify the leptin-asthma
a s s o c i a t i o n — t h i si ss u g g e s t e db yt h es t u d yb yG u l e re ta l .
[57] but has not been convincingly proven by a statistically
significant test of interaction between leptin and atopy on
asthma outcomes in any study. Finally, leptin concentrations
in children are more purely reflective of BMI than in adults
in the absence of the modifying effect of sex hormones.
In a small clinical study of obese women undergoing
bariatric surgery, visceral (i.e., omental) adipose tissue from
asthmatics showed greater expression of leptin than controls
after adjustment for BMI, even though no differences in
serum concentrations were reported [36]. Greater omental
adipose tissue expression of leptin was also strongly related
toairwayhyperresponsiveness(i.e.,lowermethacholinePC20
values; Figure 5), while serum leptin concentrations were
not similarly associated [36]. As discussed above, it is pos-
s i b l et h a tl e p t i ne x p r e s s i o ni no m e n t a la d i p o s et i s s u ei sa
markerforotheradiposetissuedependenteffectsthatmodify
asthma.
There is also a recent human ex vivo cell-based study that
supports a role for leptin in obesity-related asthma. Primary
alveolar macrophages derived from overweight/obese adults
with asthma generated greater levels of proinflammatory
cytokines (such as IL-8 and TNF-𝗼) after stimulation with
leptin than macrophages derived from either normal weight
asthmatics or obese nonasthmatics [117]. It is conceivable
that this proinflammatory macrophage phenotype, in the
context of high concentrations of serum leptin in obesity,
maycontributetothepathogenesisofasthmaassociatedwith
obesity [117].
(ii)AsthmaSeverity.Althoughstillinconclusive,existingdata
suggest that high serum leptin concentrations are associated
with greater asthma severity, particularly among prepubertal
boys and peripubertal and postpubertal girls (Table 1).
Clinic-based studies of prepubertal asthmatic children,
mostlyboys,showedthatgreaterserumleptinconcentrations
were associated with greater clinical asthma severity [61],10 Journal of Allergy
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Figure5:Relationshipbetweenvisceral(omental)fatleptinexpres-
sion and methacholine airway reactivity in morbidly obese women
with asthma at the time of bariatric surgery (rho = −0.8; 𝑃 = 0.001
for Spearman’s correlation). Reproduced with permission of the
American Thoracic Society. Copyright © 2013 American Thoracic
Society. Official Journal of the American Thoracic Society [36].
lower peak expiratory flow rates [60], greater severity of
exerciseinducedbronchoconstriction[56],andhigherserum
total IgE concentrations [57]. Further, some studies have
found these associations to be independent of BMI [56, 61].
In another study of peripubertal/postpubertal asthmatic
subjects, Kattan et al. found a positive correlation between
serum leptin and maximum asthma symptom days among
girls. No such associations were found among boys, but sex
interactionsorBMI-adjustedresultswerenotreportedbythe
authors [62].
As was the case for asthma prevalence, the association
between serum leptin and asthma severity is less consistent
inadultsthaninchildren.Asmallcase-controlstudyshowed
that high serum leptin concentrations may discriminate
women with severe asthma from mild/moderate asthma,
although this association may be confounded by the remark-
ably different BMI values between the groups [70]. Although
s e r u ml e p t i nw a sn o tc o r r e l a t e dw i t ha i r w a yi n fl a m m a t o r y
markers such as exhaled breath condensate-pH or exhaled
nitricoxide(FeNO)levelsamongsubjectswithasthma,itwas
inversely correlated with FEV1/FVC ratio in the subgroup
with mild/moderate asthma [70]. Another small clinic-based
case-control study by Holguin et al. showed no associa-
tions between serum or BAL leptin and lung inflammatory
biomarkers [25].
(iii) Subgroup Effects. Although the association between
serum leptin and asthma prevalence or severity may be
stronger and more consistent in specific population sub-
groups [57, 63, 66, 67, 118] such as prepubertal boys, peripu-
bertal or postpubertal girls, and premenopausal women, the
studies do not demonstrate a statistically significant sex,
menopause, or age interaction. Similarly, significant interac-
tions between serum leptin and atopy or smoking on asthma
outcomes have not been reported.
Even in studies demonstrating a leptin-asthma associ-
ation, serum leptin does not appear to be the only interme-
diary factor that explains the obesity-asthma association. For
example,Soodetal.[66]showedthattheassociationbetween
BMI and asthma in women was only slightly attenuated
after adjustment for serum leptin concentration. Hence,
other metabolic pathways and/or mechanical factors likely
contribute to the obesity-asthma association.
(iv)DirectionofAssociation.Insensitizedmice,allergeninha-
lation increases serum leptin concentrations [109]. Among
humans with mild atopic asthma, transient bronchoprovo-
cation from an experimental inhalational allergen challenge
does not acutely affect serum leptin concentrations [75]. On
the other hand, severe asthma exacerbations requiring hos-
p i t a l i z a t i o na r ea s s o c i a t e dw i t hat r a n s i e n ti n c r e a s ei ns e r u m
leptin concentrations [70]. As discussed above, hypoxemia
consequent to bronchoconstriction or systemic spillover of
airway inflammation in severe asthma exacerbations may
increase secretion of leptin from adipose tissue [70]. Since
there are no longitudinal studies examining the associa-
tion between high serum leptin concentrations and human
asthma, the temporal sequence for this association cannot be
definitively established.
In summary, although leptin and its receptors are
expressed in human airway cells, our understanding of the
relationship between leptin and asthma is still evolving.
Current evidence suggests that systemic leptin or visceral fat
expression of leptin may be associated with greater asthma
prevalence and/or severity, particularly among prepubertal
boys, peripubertal and postpubertal girls, and women. It
remains to be established whether modulation of leptin,
independent of BMI, may be helpful in asthma prevention or
treatment.
4. Resistin
Resistin (or “resistance to insulin”), a proinflammatory
adipokine originally discovered in mice, was named for its
ability to resist insulin action [119]. Resistin belongs to the
RELM/FIZZ family that includes three additional cysteine-
rich secretory proteins that share homology with resistin
(called resistin-like molecules or RELM, namely, RELM-𝗼,
RELM-𝗽,a n dR E L M - 𝗾). Studies on animals suggest that
resistin and resistin-like molecules may induce inflamma-
tion, angiogenesis, and smooth muscle cell proliferation,
all processes that are relevant to asthma pathogenesis [120,
121]. Interestingly, resistin induced vascular smooth muscle
proliferationisinhibitedbyadiponectin[122],suggestingthat
not only the total concentrations but also the balance of pro-
and anti-inflammatory adipokines may be important.
Much less data exists addressing a possible relationship
between resistin and asthma than that existing for either lep-
t i no ra d i p o n e c t i na n da s t h m a .I n t e r e s t i n g l y ,h u m a ns t u d i e s
of resistin show associations opposite to those expected from
in vitro studiesofresistin.Inastudy ofchildrenby Kimetal.,
atopic asthmatics had lower resistin levels than nonatopic
asthmaticsandcontrols[55].TherewasanegativecorrelationJournal of Allergy 11
between serum resistin and eosinophil counts or serum
total IgE and a positive correlation with methacholine PC20
(implying lower airway hyperresponsiveness) [55]. Multiple
regression analysis revealed that after adjustment for other
adiposity measures such as BMI and serum leptin and
adiponectin, low serum resistin concentrations were still
strongly predictive of asthma [55].
5. Summary
Although murine data are convincing, it is less clear whether
adiponectin, leptin, or resistin plays a role in modulating
asthmariskand/orseverityinhumansubjects,althoughmost
of the human data are still limited to association studies.
There are many possible explanations for the conflicting
findings, as discussed above. Most of the human studies
described above did not provide phenotypic characterization
ofasthmatics.Inmurinestudies,thereareopposingeffectsof
adiponectin depending on whether the asthma model used
was an allergic one or one related to oxidative stress. Hence,
it is conceivable that adipokines may only be important for
certain phenotypes of asthma. Indeed it is possible that the
associations observed in certain subgroups (i.e., prepubertal
boys) may relate to greater uniformity of asthma phenotypes
within these populations. Finally, it is likely that adipokines
are only one part of the obesity-asthma puzzle. Mechanical,
developmental, hormonal, genetic, and epigenetic effects of
obesity may also affect both asthma prevalence and severity
in obese humans.
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